1. Scrip

Merck Positions MK-8591 As Backbone For HIV Treatment And Prophylaxis

 
• By Joseph Haas

First-in-class antiviral could be a potential backbone for combo regimens and entry into PrEP. New data releases at IAS highlight potential in both settings.

Pills for Pre-Exposure Prophylaxis (PrEP) to prevent HIV with PrEP text engraved
Merck hopes to follow Gilead as the second company into the HIV PrEP space

Merck & Co. Inc. views its first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI) MK-8591 (islatravir) as a potential backbone agent for combination therapy in the treatment setting and also a means for entry into the pre-exposure prophylaxis (PrEP) market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D